Logo image of XBIT

XBIOTECH INC (XBIT) Stock Fundamental Analysis

NASDAQ:XBIT - Nasdaq - CA98400H1029 - Common Stock - Currency: USD

3.22  +0.01 (+0.31%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to XBIT. XBIT was compared to 549 industry peers in the Biotechnology industry. XBIT has a great financial health rating, but its profitability evaluates not so good. XBIT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year XBIT has reported negative net income.
In the past year XBIT has reported a negative cash flow from operations.
In the past 5 years XBIT always reported negative net income.
In the past 5 years XBIT reported 4 times negative operating cash flow.
XBIT Yearly Net Income VS EBIT VS OCF VS FCFXBIT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

1.2 Ratios

XBIT's Return On Assets of -21.67% is fine compared to the rest of the industry. XBIT outperforms 76.87% of its industry peers.
With an excellent Return On Equity value of -22.56%, XBIT belongs to the best of the industry, outperforming 83.42% of the companies in the same industry.
Industry RankSector Rank
ROA -21.67%
ROE -22.56%
ROIC N/A
ROA(3y)-14.6%
ROA(5y)-10.66%
ROE(3y)-15.43%
ROE(5y)-11.2%
ROIC(3y)N/A
ROIC(5y)N/A
XBIT Yearly ROA, ROE, ROICXBIT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50

1.3 Margins

XBIT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XBIT Yearly Profit, Operating, Gross MarginsXBIT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

More info and screens

9

2. Health

2.1 Basic Checks

Compared to 1 year ago, XBIT has about the same amount of shares outstanding.
XBIT has less shares outstanding than it did 5 years ago.
The debt/assets ratio for XBIT is higher compared to a year ago.
XBIT Yearly Shares OutstandingXBIT Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
XBIT Yearly Total Debt VS Total AssetsXBIT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

XBIT has an Altman-Z score of 7.61. This indicates that XBIT is financially healthy and has little risk of bankruptcy at the moment.
XBIT's Altman-Z score of 7.61 is amongst the best of the industry. XBIT outperforms 83.97% of its industry peers.
There is no outstanding debt for XBIT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.61
ROIC/WACCN/A
WACCN/A
XBIT Yearly LT Debt VS Equity VS FCFXBIT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

A Current Ratio of 29.15 indicates that XBIT has no problem at all paying its short term obligations.
XBIT's Current ratio of 29.15 is amongst the best of the industry. XBIT outperforms 97.27% of its industry peers.
XBIT has a Quick Ratio of 29.15. This indicates that XBIT is financially healthy and has no problem in meeting its short term obligations.
XBIT has a Quick ratio of 29.15. This is amongst the best in the industry. XBIT outperforms 97.27% of its industry peers.
Industry RankSector Rank
Current Ratio 29.15
Quick Ratio 29.15
XBIT Yearly Current Assets VS Current LiabilitesXBIT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

0

3. Growth

3.1 Past

XBIT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -28.07%.
EPS 1Y (TTM)-28.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
XBIT Yearly Revenue VS EstimatesXBIT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 10M 20M 30M 40M
XBIT Yearly EPS VS EstimatesXBIT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2019 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

XBIT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
XBIT Price Earnings VS Forward Price EarningsXBIT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
XBIT Per share dataXBIT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for XBIT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

XBIOTECH INC

NASDAQ:XBIT (8/20/2025, 8:00:02 PM)

3.22

+0.01 (+0.31%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2025-08-11
Earnings (Next)11-11 2025-11-11
Inst Owners14.89%
Inst Owner Change-23.87%
Ins Owners36.61%
Ins Owner Change0%
Market Cap98.18M
Analysts82.86
Price TargetN/A
Short Float %2.19%
Short Ratio4.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.56
P/tB 0.56
EV/EBITDA N/A
EPS(TTM)-1.3
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-1.04
FCFYN/A
OCF(TTM)-1
OCFYN/A
SpS0
BVpS5.73
TBVpS5.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -21.67%
ROE -22.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-14.6%
ROA(5y)-10.66%
ROE(3y)-15.43%
ROE(5y)-11.2%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 64.77%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 29.15
Quick Ratio 29.15
Altman-Z 7.61
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)39.36%
Cap/Depr(5y)83.56%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-28.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.18%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-9.27%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-111.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-110.08%
OCF growth 3YN/A
OCF growth 5YN/A